Evidence map›Paper›PMID 42418010›Full record

ArticleCancer immunology, immunotherapy : CII2026

Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model.

Koki Murakami, Noriyuki Kijima, Hideki Kuroda, Tetsuro Tachi, Shunya Ikeda, Kanji Nakagawa, Yuki Wada, Tatsuya Hagioka, Naoko Hatanaka, Ryuichi Hirayama and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Koki MurakamiDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Noriyuki KijimaDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan. n-kijima@nsurg.med.osaka-u.ac.jp.
Hideki KurodaDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Tetsuro TachiDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Shunya IkedaWorld Premier International Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan.
Kanji NakagawaDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Yuki WadaDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Tatsuya HagiokaDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Naoko HatanakaDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Ryuichi HirayamaDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Haruhiko KishimaDepartment of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Naoki HosenWorld Premier International Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.

Funding

AMED (Japan Agency for Medical Research and Development) 24ama221338h0001JSPS KAKENHI Grant 22K09231
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is among the most malignant primary brain tumors, necessitating the development of novel therapies. Intracranial injection of chimeric antigen receptor (CAR)-T cell therapy is effective against GBM. However, whether intracranially injected CAR-T cells persist in the brain for long periods is unclear. In this study, we established a syngeneic murine model of GBM by injecting GL261 murine GBM cells expressing human B7-H3. After confirming tumor engraftment, murine T cells transduced with CAR-targeting human B7-H3 were injected intratumorally. Reduced tumor burden and enhanced survival were observed in mice injected with B7-H3 CAR-T cells compared with those injected with control T cells. CAR-T cells were distinctly detected in the brain 1 week after CAR-T cell injection, but disappeared 2 weeks after injection. In the syngeneic mouse model, intracranially injected CAR-T cells have the potential to eradicate GBM but do not persist in the brain for long, suggesting that intracranial injections of CAR-T cells need to be repeatedly administered, as has been done in several clinical trials. It will be important to develop strategies to enhance persistence of CAR-T cells in the brain.

Indexed as

BrainBrain NeoplasmsGlioblastomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsB7 AntigensCell Line, TumorDisease Models, AnimalHumansMiceMice, Inbred C57BLB7 AntigensReceptors, Chimeric AntigenB7-H3CAR-T cell therapyGlioblastomaPersistence

Identifiers

PMID42418010
PMCPMC13638904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.